Van ECK Associates Corp Grows Stock Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Van ECK Associates Corp raised its position in West Pharmaceutical Services, Inc. (NYSE:WSTGet Rating) by 7.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,046 shares of the medical instruments supplier’s stock after acquiring an additional 950 shares during the quarter. Van ECK Associates Corp’s holdings in West Pharmaceutical Services were worth $3,210,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of WST. CX Institutional purchased a new position in shares of West Pharmaceutical Services during the second quarter valued at about $28,000. Householder Group Estate & Retirement Specialist LLC purchased a new position in shares of West Pharmaceutical Services during the third quarter valued at about $36,000. Allworth Financial LP increased its position in shares of West Pharmaceutical Services by 70.8% during the second quarter. Allworth Financial LP now owns 123 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 51 shares during the period. Private Trust Co. NA increased its position in shares of West Pharmaceutical Services by 194.6% during the third quarter. Private Trust Co. NA now owns 165 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 109 shares during the period. Finally, Glassman Wealth Services increased its position in shares of West Pharmaceutical Services by 57.0% during the second quarter. Glassman Wealth Services now owns 146 shares of the medical instruments supplier’s stock valued at $44,000 after buying an additional 53 shares during the period. Hedge funds and other institutional investors own 91.51% of the company’s stock.

Insider Activity at West Pharmaceutical Services

In related news, CEO Eric Mark Green sold 44,000 shares of the stock in a transaction that occurred on Monday, December 5th. The shares were sold at an average price of $238.99, for a total transaction of $10,515,560.00. Following the transaction, the chief executive officer now owns 114,922 shares in the company, valued at $27,465,208.78. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on WST shares. UBS Group started coverage on shares of West Pharmaceutical Services in a research note on Wednesday, November 30th. They set a “neutral” rating and a $250.00 price objective on the stock. KeyCorp dropped their price objective on shares of West Pharmaceutical Services from $350.00 to $315.00 and set an “overweight” rating on the stock in a research note on Friday, December 2nd. Bank of America lowered shares of West Pharmaceutical Services from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $385.00 to $250.00 in a research note on Friday, October 28th. StockNews.com started coverage on shares of West Pharmaceutical Services in a research note on Wednesday, October 12th. They set a “hold” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of West Pharmaceutical Services in a research note on Tuesday, December 13th. They set a “hold” rating and a $250.00 price objective on the stock. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, West Pharmaceutical Services has a consensus rating of “Hold” and a consensus price target of $266.25.

West Pharmaceutical Services Trading Down 1.3 %

Shares of NYSE WST opened at $248.09 on Friday. The firm’s 50 day moving average price is $235.01 and its 200-day moving average price is $269.82. The company has a market cap of $18.37 billion, a PE ratio of 29.93, a P/E/G ratio of 2.20 and a beta of 1.12. West Pharmaceutical Services, Inc. has a 52-week low of $206.19 and a 52-week high of $424.00. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.89 and a current ratio of 3.80.

West Pharmaceutical Services (NYSE:WSTGet Rating) last issued its earnings results on Thursday, October 27th. The medical instruments supplier reported $2.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.12 by ($0.09). The firm had revenue of $686.90 million during the quarter, compared to the consensus estimate of $730.64 million. West Pharmaceutical Services had a return on equity of 28.15% and a net margin of 21.68%. On average, equities research analysts expect that West Pharmaceutical Services, Inc. will post 8.18 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 1st. Investors of record on Wednesday, January 25th will be given a dividend of $0.19 per share. The ex-dividend date is Tuesday, January 24th. This represents a $0.76 dividend on an annualized basis and a yield of 0.31%. West Pharmaceutical Services’s dividend payout ratio (DPR) is 9.17%.

West Pharmaceutical Services Profile

(Get Rating)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Featured Articles

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.